Background: Ovarian hyperstimulation syndrome (OHSS) is a frequent serious complication in controlled ovarian hyperstimulation for in vitro fertilization. Among the treatments for OHSS, the continuation of GnRH agonist during the luteal phase has been recently suggested.
Materials and methods: Five patients at risk for OHSS received 0.1 mg triptorelin for one week after embryo transfer in order to prevent OHSS.
Results: All the five patients developed mild symptoms. None of them required hospitalization.
Conclusion: Although the pathophysiology of OHSS and the effects of GnRH agonist during the luteal phase remain unclear, the continuation of GnRH agonist seems to be a safe and effective treatment for OHSS.